Edition:
India

AveXis Inc (AVXS.OQ)

AVXS.OQ on NASDAQ Stock Exchange Global Select Market

108.25USD
2:29am IST
Change (% chg)

$-1.92 (-1.74%)
Prev Close
$110.17
Open
$109.34
Day's High
$110.29
Day's Low
$105.78
Volume
363,602
Avg. Vol
168,167
52-wk High
$119.00
52-wk Low
$50.59

Select another date:

Tue, Jan 16 2018

BRIEF-Avexis Announces Expanded Clinical Development Program For AVXS-101 In Spinal Muscular Atrophy

* AVEXIS ANNOUNCES EXPANDED CLINICAL DEVELOPMENT PROGRAM FOR AVXS-101 IN SPINAL MUSCULAR ATROPHY

BRIEF-Regenxbio And Avexis Announce Expansion Of Relationship For Spinal Muscular Atrophy treatments

* REGENXBIO AND AVEXIS ANNOUNCE EXPANSION OF RELATIONSHIP THROUGH AMENDED LICENSE AGREEMENT FOR THE DEVELOPMENT AND COMMERCIALIZATION OF TREATMENTS FOR SPINAL MUSCULAR ATROPHY

BRIEF-Avexis Inc Plans To Request A Pre-BLA Meeting For AVXS-101 In Q2 ​

* AVEXIS ANNOUNCES ALIGNMENT WITH FDA ON NEXT STEPS TOWARD A BLA SUBMISSION FOR AVXS-101 IN SMA TYPE 1

BRIEF-Avexis plans to initiate Phase 1 trial in SMA Type 2

* AVEXIS ANNOUNCES PLAN TO INITIATE PHASE 1 TRIAL IN SMA TYPE 2 UTILIZING INTRATHECAL DELIVERY OF AVXS-101 Source text for Eikon: Further company coverage:

BRIEF-Avexis posts Q3 loss per share $1.52

* Avexis reports third quarter 2017 financial and operating results

BRIEF-Avexis Inc CFO Thomas Dee resigns

* Avexis Inc - ‍on October 14 Thomas J. Dee resigned as senior vice president, chief financial officer - SEC filing

BRIEF-AveXis to report top-line data from phase 1 clinical trial of AVXS-101

* AveXis to report top-line data from the Phase 1 clinical trial of AVXS-101 in SMA Type 1 at the International Annual Congress Of The World Muscle Society

BRIEF-Avexis to initiate pivotal trial of AVXS-101 in SMA type 1

* Avexis announces plan to initiate pivotal trial of AVXS-101 in SMA type 1 using product from new GMP commercial process

BRIEF-AveXis reports Q2 loss per share $2.07

* AveXis reports second quarter 2017 financial and operating results

Select another date: